Market Overview

The China generic drug market size was USD 64.1 Billion in 2024 and is projected to reach USD 154.6 Billion by 2033, growing at a CAGR of 10.27% between 2025 and 2033. Market expansion is driven by patent expirations on brand-name drugs, government initiatives promoting generics, cost-containment measures, and rising chronic disease prevalence. The China Generic Drug Market report offers deep insights into growth trends and market dynamics.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

China Generic Drug Market Key Takeaways

• Current Market Size: USD 64.1 Billion in 2024
• CAGR: 10.27% (2025-2033)
• Forecast Period: 2025-2033
• Patent expirations on brand-name drugs facilitate market entry for generic drug manufacturers.
• Government support includes centralized drug procurement programs encouraging generics use in public hospitals.
• Price caps and insurance promotion increase generic drugs’ adoption.
• Chronic diseases like diabetes (with 13% prevalence among adults in 2021) drive demand for affordable long-term medication.

Sample Request Link: https://www.imarcgroup.com/China-Generic-Drug-Market/requestsample

Market Growth Factors

After the patent on a prescription drug expires, generic drug manufacturers can produce a bioequivalent version of the drug at a lower price (the "patent cliff"). Generic drugs tend to replace the brand name version due to their lower price, which leads to a substitution effect for the consumer to purchase the lower priced generic drug. The Chinese government encourages use of generic drugs to improve access and reduce cost. It also promotes the use of generics in public hospitals via the centralized drug procurement (CDP) program, which seeks to increase competition in the market. The NMPA has simplified standards of registration of generics with standards equivalent to the originator drug and endorsed programs such as the Quality Consistency Evaluation (QCE) to improve domestic generic drug quality and improve consumer confidence.

Due to the increasing cost of healthcare in China, ways were sought by the healthcare provider and government to help control the costs. Generic drugs are usually less expensive than their brand name equivalents. In China, a new national bulk-buy centralized procurement program has been created to directly negotiate prices and to encourage the use of generics in hospitals. This is done by implementing price controls on certain essential drugs and creating financial incentives to prescribe generic over branded drugs. Insurers and healthcare providers also encourage the use of generics.

Chronic diseases such as diabetes, high blood pressure, cardiovascular diseases, and cancer are common. They require lifelong medication and a constant supply of low-cost drugs. In China, for example, there were 1079960800 adults in 2021 and 13% of them were diabetic (140869600). Generics, because of their lower cost, are particularly well-suited for the treatment of chronic conditions, and other developments in medicine, such as better diagnostics, also contribute to a longer time until diagnosis with chronic diseases as well as longer times on a chronic medication. The trend in the generics market is expected to continue for the foreseeable future.

Market Segmentation

Therapy Area Insights

• Central Nervous System: Includes analysis of generics used for neurological conditions, indicating expanding applications.
• Cardiovascular: Covers generic drugs for heart-related diseases, an essential segment given chronic disease prevalence.
• Dermatology: Encompasses generics targeting skin-related conditions.
• Genitourinary/Hormonal: Analyzes generic medications in this category.
• Respiratory: Includes generic drugs for respiratory diseases.
• Rheumatology: Covers generics for autoimmune and joint disorders.
• Diabetes: Focuses on generic treatments for diabetes management.
• Oncology: Includes generic cancer treatments.
• Others: Covers remaining therapy areas.

Drug Delivery Insights

• Oral: The primary drug delivery mode covered by generic drugs.
• Injectables: Analysis of injectable generic medications.
• Dermal/Topical: Includes generics applied to the skin.
• Inhalers: Covers inhalable generic drug forms.

Distribution Channel Insights

• Retail Pharmacy: Analysis of generic drug sales through retail outlets.
• Hospital Pharmacy: Includes generics distributed in hospitals.
• Online Pharmacy: Covers online sales channels for generics.

Request Customization:

https://www.imarcgroup.com/request?type=report&id=23430&flag=E 

Regional Insights

The report covers major regions including North China, East China, South Central China, Southwest China, Northwest China, and Northeast China. However, the source does not specify the dominant region or provide explicit market shares or growth rates.

Recent Developments & News

In October 2023, the China National Medical Products Administration (NMPA) introduced a regulatory requirement mandating that Abbreviated New Drug Applications (ANDAs) for generic drugs without reference listed drugs must demonstrate clinical value. This change aims to ensure generic drugs are both clinically and chemically effective.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302